-
1
-
-
84866597106
-
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
ESMO Guidelines Working Group
-
Cardoso F, Harbeck N, Fallowfield L, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7):vii11-19
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 7
-
-
Cardoso, F.1
Harbeck, N.2
Fallowfield, L.3
-
2
-
-
41849091764
-
A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)
-
Stockler M, Sourjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). Proceedings of 2007 American Society of Clinical Oncology Annual Meeting; Chicago J Clin Oncol 2007. 25(Suppl 18):1031
-
(2007)
Proceedings of 2007 American Society of Clinical Oncology Annual Meeting; Chicago J Clin Oncol
, vol.25
, Issue.SUPPL. 18
, pp. 1031
-
-
Stockler, M.1
Sourjina, T.2
Grimison, P.3
-
3
-
-
0034778024
-
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. A reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer
-
Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. A reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54
-
(2001)
Ann Oncol
, vol.12
, Issue.9
, pp. 1247-1254
-
-
Oshaughnessy, J.A.1
Blum, J.2
Moiseyenko, V.3
-
4
-
-
0035476911
-
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
-
Blum JL, Dieras V, Lo Russo P, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92(7): 1759-68
-
(2001)
Cancer
, vol.92
, Issue.7
, pp. 1759-1768
-
-
Blum, J.L.1
Dieras, V.2
Lo Russo, P.3
-
5
-
-
84876297448
-
Targeted therapies of solid cancers: New options, new challenges
-
Awada A, Aftimos PG. Targeted therapies of solid cancers: new options, new challenges. Curr Opin Oncol 2013;25(3): 296-304
-
(2013)
Curr Opin Oncol
, vol.25
, Issue.3
, pp. 296-304
-
-
Awada, A.1
Aftimos, P.G.2
-
6
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
-
(2012)
N Engl J Med
, vol.366
, Issue.6
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
-
8
-
-
84868520609
-
EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer
-
Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19): 1783-91
-
(2012)
N Engl J Med
, vol.367
, Issue.19
, pp. 1783-1791
-
-
Verma, S.1
Miles, D.2
Gianni, L.3
-
9
-
-
32944482677
-
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer
-
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803
-
(2005)
J Clin Oncol
, vol.23
, Issue.31
, pp. 7794-7803
-
-
Gradishar, W.J.1
Tjulandin, S.2
Davidson, N.3
-
10
-
-
36849071808
-
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
-
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25(33):5210-17
-
(2007)
J Clin Oncol
, vol.25
, Issue.33
, pp. 5210-5217
-
-
Thomas, E.S.1
Gomez, H.L.2
Li, R.K.3
-
11
-
-
79952487463
-
EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
-
Cortes J, O'Shaughnessy J, Loesch D, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377(9769): 14-923
-
(2011)
Lancet
, vol.377
, Issue.9769
, pp. 14-923
-
-
Cortes, J.1
O'shaughnessy, J.2
Loesch, D.3
-
12
-
-
84901452349
-
-
Nektar Therapeutics. Last accessed 16 June
-
Nektar Therapeutics. The BEACON Study (Breast Cancer Outcomes With NKTR-102). Available from:Www. clinicaltrials. gov/ ct2/results? term=NCT01492101&Search=Search [Last accessed 16 June 2013]
-
(2013)
The BEACON Study (Breast Cancer Outcomes with NKTR-102)
-
-
-
13
-
-
0037096755
-
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
-
O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23
-
(2002)
J Clin Oncol
, vol.20
, Issue.12
, pp. 2812-2823
-
-
O'shaughnessy, J.1
Miles, D.2
Vukelja, S.3
-
14
-
-
50549096593
-
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
-
Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26(24):3950-7
-
(2008)
J Clin Oncol
, vol.26
, Issue.24
, pp. 3950-3957
-
-
Albain, K.S.1
Nag, S.M.2
Calderillo-Ruiz, G.3
-
15
-
-
0032006059
-
Microtubules and actin filaments: Dynamic targets for cancer chemotherapy
-
Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10(1):123-30
-
(1998)
Curr Opin Cell Biol
, vol.10
, Issue.1
, pp. 123-130
-
-
Jordan, M.A.1
Wilson, L.2
-
16
-
-
0022709534
-
Halichondrins: Antitumor polyether macrolides from a marine sponge
-
Hirata Y, Uemura D. Halichondrins: Antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58(5):701-10
-
(1986)
Pure Appl Chem
, vol.58
, Issue.5
, pp. 701-710
-
-
Hirata, Y.1
Uemura, D.2
-
17
-
-
23144433687
-
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
-
Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4(7): 1086-95
-
(2005)
Mol Cancer Ther
, vol.4
, Issue.7
, pp. 1086-1095
-
-
Jordan, M.A.1
Kamath, K.2
Manna, T.3
-
18
-
-
4143052665
-
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
-
Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64: 5760-6
-
(2004)
Cancer Res
, vol.64
, pp. 5760-5766
-
-
Kuznetsov, G.1
Towle, M.J.2
Cheng, H.3
-
19
-
-
33751102419
-
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin
-
Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70(6): 1866-75
-
(2006)
Mol Pharmacol
, vol.70
, Issue.6
, pp. 1866-1875
-
-
Dabydeen, D.A.1
Burnett, J.C.2
Bai, R.3
-
20
-
-
67449117538
-
Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro
-
22-26 Oct 2007 San Francisco, CA, USA. Proc Am Assoc Cancer Res. Abstract C58
-
Kuznetsov G, Ten Dyke K, Yu MJ, Littlefield BA. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro. [abstract In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22-26 Oct 2007 San Francisco, CA, USA. Proc Am Assoc Cancer Res. 2007. 48:275. Abstract C58 Available at www. aacrmeetingabstracts. org/ cgi/content/meeting
-
(2007)
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
, vol.48
, pp. 275
-
-
Kuznetsov, G.1
Ten Dyke, K.2
Yu, M.J.3
Littlefield, B.A.4
-
21
-
-
84867338601
-
Bevacizumab and breast cancer: A meta-analysis of first-line phase iii studies and a critical reappraisal of available evidence
-
Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: A meta-analysis of first-line phase iii studies and a critical reappraisal of available evidence. J Oncol 2012;2012:417673
-
(2012)
J Oncol
, vol.2012
, pp. 417673
-
-
Rossari, J.R.1
Metzger-Filho, O.2
Paesmans, M.3
-
22
-
-
84863719309
-
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial
-
Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133(3): 1067-75
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.3
, pp. 1067-1075
-
-
Brufsky, A.1
Valero, V.2
Tiangco, B.3
-
23
-
-
84859728286
-
First-line bevacizumab-containing therapy for triple-negative breast cancer: Analysis of 585 patients treated in the ATHENA study
-
Thomssen C, Pierga JY, Pritchard K, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: Analysis of 585 patients treated in the ATHENA study. Oncology 2012;82(4):218-27
-
(2012)
Oncology
, vol.82
, Issue.4
, pp. 218-227
-
-
Thomssen, C.1
Pierga, J.Y.2
Pritchard, K.3
-
24
-
-
84876970810
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
-
Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71
-
(2013)
Lancet Oncol
, vol.14
, Issue.6
, pp. 461-471
-
-
Swain, S.M.1
Kim, S.B.2
Cortés, J.3
-
25
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
-
(2006)
N Engl J Med
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.3
-
26
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103
-
(2000)
J Clin Oncol
, vol.18
, Issue.10
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
27
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire WP, Hoskins WJ, Brady M, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
-
(1996)
N Engl J Med
, vol.334
, Issue.1
, pp. 1-6
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.3
-
28
-
-
4744366279
-
TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
-
29
-
-
77957682309
-
TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376(9747):1147-54
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
30
-
-
84901387778
-
Nab-paclitaxel plus gemcitabine in pancreatic cancer
-
Abstract LBA148 25 January, San Franscisco
-
Von Hoff DD, Ervin T, Arena FP, et al. Nab-Paclitaxel Plus Gemcitabine in Pancreatic Cancer. Gastrointestinal Cancers Symposium; abstract LBA148 25 January 2012; San Franscisco
-
(2012)
Gastrointestinal Cancers Symposium
-
-
Von Hoff, D.D.1
Ervin, T.2
Arena, F.P.3
-
31
-
-
35548966042
-
EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
-
Vermorken JB, Remenar E, van Herpen C, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17): 1695-704
-
(2007)
N Engl J Med
, vol.357
, Issue.17
, pp. 1695-1704
-
-
Vermorken, J.B.1
Remenar, E.2
Van Herpen, C.3
-
32
-
-
0037083580
-
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
-
Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20(4):937-40
-
(2002)
J Clin Oncol
, vol.20
, Issue.4
, pp. 937-940
-
-
Vaughn, D.J.1
Broome, C.M.2
Hussain, M.3
-
33
-
-
0037096747
-
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial
-
Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20(12): 2824-31
-
(2002)
J Clin Oncol
, vol.20
, Issue.12
, pp. 2824-2831
-
-
Hensley, M.L.1
Maki, R.2
Venkatraman, E.3
-
34
-
-
0022378694
-
Norhalichondrin A: An antitumor polyether macrolide from a marine sponge
-
Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107(16):4796-8
-
(1985)
J Am Chem Soc
, vol.107
, Issue.16
, pp. 4796-4798
-
-
Uemura, D.1
Takahashi, K.2
Yamamoto, T.3
-
35
-
-
84856235418
-
Eribulin-A review of preclinical and clinical studies
-
Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-a review of preclinical and clinical studies. Crit Rev Oncol Hematol 2012;81(2):163-84
-
(2012)
Crit Rev Oncol Hematol
, vol.81
, Issue.2
, pp. 163-184
-
-
Swami, U.1
Chaudhary, I.2
Ghalib, M.H.3
Goel, S.4
-
36
-
-
0022709534
-
Halichondrins- antitumor polyether macrolides from a marine sponge
-
Hirata Y, Uemura D. Halichondrins- antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58(5):701-10
-
(1986)
Pure Appl Chem
, vol.58
, Issue.5
, pp. 701-710
-
-
Hirata, Y.1
Uemura, D.2
-
37
-
-
0035110756
-
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B
-
Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61(3): 1013-21
-
(2001)
Cancer Res
, vol.61
, Issue.3
, pp. 1013-1021
-
-
Towle, M.J.1
Salvato, K.A.2
Budrow, J.3
-
38
-
-
0027518597
-
Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin
-
Luduena RF, Roach MC, Prasad V, Pettit GR. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 1993;45(2): 421-7
-
(1993)
Biochem Pharmacol
, vol.45
, Issue.2
, pp. 421-427
-
-
Luduena, R.F.1
Roach, M.C.2
Prasad, V.3
Pettit, G.R.4
-
39
-
-
84975897156
-
Discovery of E7389, a fully synthetic macrocyclic ketone analog of Halichondrin B
-
CRC Press
-
Yu M, Littlefield B, Kishi Y. Discovery of E7389, a fully synthetic macrocyclic ketone analog of Halichondrin B. In: Anticancer agents from natural products. CRC Press; 2005
-
(2005)
Anticancer Agents from Natural Products
-
-
Yu, M.1
Littlefield, B.2
Kishi, Y.3
-
40
-
-
79953819478
-
-
Eisai Inc, Woodcliff Lake, NJ, USA
-
Halaven [package insert]. Eisai Inc, Woodcliff Lake, NJ, USA; 2010
-
(2010)
Halaven [Package Insert]
-
-
-
41
-
-
84901387587
-
A comparaison of PI3K inhibition by eribulin, other microtubule targeting agents and a DNA-damaging chemotherapeutic in triple negative and her2 breast cancer cell lines
-
P3-03-08 12 December 2013
-
Luyimbazi D, Luu T, Xing Q. A comparaison of PI3K inhibition by eribulin, other microtubule targeting agents and a DNA-damaging chemotherapeutic in triple negative and her2 breast cancer cell lines. Proceeding San Antonio Breast Cancer 2013; P3-03-08 12 December 2013
-
(2013)
Proceeding San Antonio Breast Cancer
-
-
Luyimbazi, D.1
Luu, T.2
Xing, Q.3
-
42
-
-
0035110756
-
In vitro and in vivi anticancer activities of synthetic macrocyclinic ketone analogues of Halochondrin B
-
Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivi anticancer activities of synthetic macrocyclinic ketone analogues of Halochondrin B. Cancer Res 2001;61(3): 1013-21
-
(2001)
Cancer Res
, vol.61
, Issue.3
, pp. 1013-1021
-
-
Towle, M.J.1
Salvato, K.A.2
Budrow, J.3
-
43
-
-
84865711913
-
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: Summary of the scientific assessment of the committee for medicinal products for human use
-
Pean E, Klaar S, Berglund EG, et al. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: Summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 2012;18(17): 4491-7
-
(2012)
Clin Cancer Res
, vol.18
, Issue.17
, pp. 4491-4497
-
-
Pean, E.1
Klaar, S.2
Berglund, E.G.3
-
44
-
-
67449147109
-
A phase i study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies
-
Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15(12):4207-12
-
(2009)
Clin Cancer Res
, vol.15
, Issue.12
, pp. 4207-4212
-
-
Goel, S.1
Mita, A.C.2
Mita, M.3
-
45
-
-
33745000162
-
A phase i pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial
-
Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. 2005 ASCO Annual Meeting Proceedings; J Clin Oncol 2005. 23(16S):3036
-
(2005)
2005 ASCO Annual Meeting Proceedings; J Clin Oncol
, vol.23
, Issue.16 S
, pp. 3036
-
-
Synold, T.W.1
Morgan, R.J.2
Newman, E.M.3
-
48
-
-
84901397289
-
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
-
574
-
Devriese LA, Wanders J, Jenner A, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Proceedings of the AACR Symposium; 2010; abstract 574
-
(2010)
Proceedings of the AACR Symposium
-
-
Devriese, L.A.1
Wanders, J.2
Jenner, A.3
-
49
-
-
67449123315
-
Phase i study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors
-
Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15(12):4213-19
-
(2009)
Clin Cancer Res
, vol.15
, Issue.12
, pp. 4213-4219
-
-
Tan, A.R.1
Rubin, E.H.2
Walton, D.C.3
-
50
-
-
67449159949
-
A phase i study of eribulin mesylate (E7389) in patients with refractory cancers
-
Abstract 446
-
Minami H, Mukohara T, Nagai S, et al. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008(Suppl 6):140; abstract 446
-
(2008)
Eur J Cancer
, Issue.SUPPL. 6
, pp. 140
-
-
Minami, H.1
Mukohara, T.2
Nagai, S.3
-
51
-
-
78649646076
-
Phase i and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial
-
Synold TW, Tsao-Wei DD, Quinn DI, et al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial. Abstract 2527 J Clin Oncol 2010;28(Suppl):7s
-
(2010)
Abstract 2527 J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Synold, T.W.1
Tsao-Wei, D.D.2
Quinn, D.I.3
-
52
-
-
77952696144
-
Phase i study of E7389/gemcitabine combination in patients with advanced solid tumors
-
Abstract e13509
-
Goel R, Chen E, Welch S, et al. Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol 2009;27(Suppl; Abstract e13509
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Goel, R.1
Chen, E.2
Welch, S.3
-
55
-
-
67649908927
-
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27(18):2954-61
-
(2009)
J Clin Oncol
, vol.27
, Issue.18
, pp. 2954-2961
-
-
Vahdat, L.T.1
Pruitt, B.2
Fabian, C.J.3
-
56
-
-
77957594393
-
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
-
Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28(25): 3922-8
-
(2010)
J Clin Oncol
, vol.28
, Issue.25
, pp. 3922-3928
-
-
Cortes, J.1
Vahdat, L.2
Blum, J.L.3
-
57
-
-
84861733607
-
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
-
Aogi K, Iwata H, Masuda N. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23(6):1441-8
-
(2012)
Ann Oncol
, vol.23
, Issue.6
, pp. 1441-1448
-
-
Aogi, K.1
Iwata, H.2
Masuda, N.3
-
58
-
-
84881474908
-
Eribulin mesylate versus ixabepilone in metastatic breast cancer patients: A randomized phase ii study comparing the incidence of peripheral neuropathy
-
Vahdat L, Garcia AA, et al. Eribulin mesylate versus ixabepilone in metastatic breast cancer patients: A randomized phase ii study comparing the incidence of peripheral neuropathy. Breast Cancer ResTreat 2013; 140(2):341-51
-
(2013)
Breast Cancer ResTreat
, vol.140
, Issue.2
, pp. 341-351
-
-
Vahdat, L.1
Garcia, A.A.2
-
59
-
-
84901410098
-
Eribulin mesylate as first line therapy for locally recurrent or metastatic HER2 negative breast cancer: Results of a phase 2, multicenter, single-arm study
-
Abstract P3-13-05 12 December
-
McIntyre K, O'Shaughenessy J, Schwartzberg L, et al. Eribulin mesylate as first line therapy for locally recurrent or metastatic HER2 negative breast cancer: Results of a phase 2, multicenter, single-arm study. Proceedings of the 2013 San Antonio Breast Cancer Symposium; abstract P3-13-05 12 December 2013
-
(2013)
Proceedings of the 2013 San Antonio Breast Cancer Symposium
-
-
McIntyre, K.1
O'shaughenessy, J.2
Schwartzberg, L.3
-
60
-
-
84995781682
-
Phase 2, multicenter, single arm study of Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
-
abstract P4-12-12 13 December
-
Wilks S, Puhalla S, O'shaughnessy J, et al. Phase 2, multicenter, single arm study of Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Proceedings of the 2013 San Antonio Breast Cancer Symposium 2013; abstract P4-12-12 13 December 2013
-
(2013)
Proceedings of the 2013 San Antonio Breast Cancer Symposium 2013
-
-
Wilks, S.1
Puhalla, S.2
O'shaughnessy, J.3
-
61
-
-
84901458189
-
Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide preliminary results from a phase 2, single-arm feasibility study
-
San Antonio, TX, USA, abstract P1-13-11 11 December
-
Traina TA, Hudis C, Fornier M, et al. Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: Preliminary results from a phase 2, single-arm feasibility study. Proceedings of the 2012 San Antonio Breast Cancer Symposium; San Antonio, TX, USA, abstract P1-13-11 11 December 2012
-
(2012)
Proceedings of the 2012 San Antonio Breast Cancer Symposium
-
-
Traina, T.A.1
Hudis, C.2
Fornier, M.3
-
62
-
-
84901462886
-
Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal estrogen positive early stage breast cancer: Phase 2, multicenter, single center study
-
San Antonio, TX, USA, abstract 563
-
Smith J, Rege J, Meniar H, et al. Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal estrogen positive early stage breast cancer: Phase 2, multicenter, single center study. 2013 ASCO Annual Meeting Proceedings; J Clin Oncol 2013. 31; San Antonio, TX, USA, abstract 563
-
(2013)
2013 ASCO Annual Meeting Proceedings; J Clin Oncol
, vol.31
-
-
Smith, J.1
Rege, J.2
Meniar, H.3
-
63
-
-
84941080119
-
Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients
-
San Antonio, TX, USA, abstract P3-14-14 12 December
-
Giordano SB, Jeruss JS, Bethke KP, et al. Neoadjuvant phase II trial with carboplatin and eribulin in triple negative breast cancer patients. Proceedings of the 2013 San Antonio Breast Cancer Symposium; San Antonio, TX, USA, abstract P3-14-14 12 December 2013
-
(2013)
Proceedings of the 2013 San Antonio Breast Cancer Symposium
-
-
Giordano, S.B.1
Jeruss, J.S.2
Bethke, K.P.3
-
64
-
-
84855686899
-
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer
-
Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 2012;13(1):31-8
-
(2012)
Clin Lung Cancer
, vol.13
, Issue.1
, pp. 31-38
-
-
Spira, A.I.1
Iannotti, N.O.2
Savin, M.A.3
-
65
-
-
84859422181
-
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
-
de Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012; 23(5):1241-9
-
(2012)
Ann Oncol
, vol.23
, Issue.5
, pp. 1241-1249
-
-
De Bono, J.S.1
Molife, L.R.2
Sonpavde, G.3
-
66
-
-
84856236087
-
ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
-
Stein MN, Chen Y, Hudes GR, et al. ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2010. 28(Suppl 15):4556
-
(2010)
2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 4556
-
-
Stein, M.N.1
Chen, Y.2
Hudes, G.R.3
-
67
-
-
84862255849
-
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
-
Renouf DJ, Tang PA, Major P, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2012;30(3):1203-7
-
(2012)
Invest New Drugs
, vol.30
, Issue.3
, pp. 1203-1207
-
-
Renouf, D.J.1
Tang, P.A.2
Major, P.3
-
68
-
-
80053383254
-
European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes
-
Schöffski P, Ray-Coquard IL, Cioffi A, et al. European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG. Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12(11):1045-52
-
(2011)
Lancet Oncol
, vol.12
, Issue.11
, pp. 1045-1052
-
-
Schöffski, P.1
Ray-Coquard, I.L.2
Cioffi, A.3
-
69
-
-
84860217796
-
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study
-
Hensley ML, Kravetz S, Jia X, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer 2012; 118(9):2403-10
-
(2012)
Cancer
, vol.118
, Issue.9
, pp. 2403-2410
-
-
Hensley, M.L.1
Kravetz, S.2
Jia, X.3
-
70
-
-
79957508233
-
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618
-
Arnold SM, Moon J, Williamson SK. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 2011;29(2):352-9
-
(2011)
Invest New Drugs
, vol.29
, Issue.2
, pp. 352-359
-
-
Arnold, S.M.1
Moon, J.2
Williamson, S.K.3
-
71
-
-
78649667759
-
Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEPsponsored trial
-
Quinn DI, Aparicio A, Tsao-Wei DD, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEPsponsored trial. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol 2010. 28(Suppl 15): 4539
-
(2010)
2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); J Clin Oncol
, vol.28
, Issue.SUPPL. 15
, pp. 4539
-
-
Quinn, D.I.1
Aparicio, A.2
Tsao-Wei, D.D.3
-
74
-
-
84879465606
-
A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
-
Kaufmann PA, Awada A, Twelves C, et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 2012;72(Suppl 24):S6-
-
(2012)
Cancer Res
, vol.72
, Issue.SUPPL. 24
-
-
Kaufmann, P.A.1
Awada, A.2
Twelves, C.3
-
75
-
-
84901449543
-
Effect on age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
-
Abstract P3-13-04 12 December
-
Kaufman PA, Yelle L, Cortes J, et al. Effect on age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. 2013 San Antonio Breast Cancer Symposium; abstract P3-13-04 12 December 2013
-
(2013)
2013 San Antonio Breast Cancer Symposium
-
-
Kaufman, P.A.1
Yelle, L.2
Cortes, J.3
-
76
-
-
0034764361
-
Psychological sequelae and alopecia among women with cancer
-
McGarvey EL, Baum LD, Pinkerton RC, et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9(6):283-9
-
(2001)
Cancer Pract
, vol.9
, Issue.6
, pp. 283-289
-
-
McGarvey, E.L.1
Baum, L.D.2
Pinkerton, R.C.3
-
80
-
-
34548178720
-
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
-
Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007;110(5):965-72
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 965-972
-
-
Burstein, H.J.1
Keshaviah, A.2
Baron, A.D.3
-
81
-
-
84879474820
-
CYP3A4 22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
-
de Graan AJ, Elens L, Sprowl JA, et al. CYP3A4 22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clin Cancer Res 2013; 19(12):3316-24
-
(2013)
Clin Cancer Res
, vol.19
, Issue.12
, pp. 3316-3324
-
-
De Graan, A.J.1
Elens, L.2
Sprowl, J.A.3
-
82
-
-
84871745713
-
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer
-
Lopes G, Glück S, Avancha K, Montero AJ. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2013;137(1):187-93
-
(2013)
Breast Cancer Res Treat
, vol.137
, Issue.1
, pp. 187-193
-
-
Lopes, G.1
Glück, S.2
Avancha, K.3
Montero, A.J.4
-
83
-
-
84901395669
-
-
to-BBB technologies B. V. An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma
-
to-BBB technologies B. V. An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Available from:Www. clinicaltrials. gov/ct2/results? term=NCT01386580&Search=Search
-
-
-
-
84
-
-
84873030031
-
Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice
-
Yu Y, Desjardins C, Saxton P, et al. Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. Int J Pharm 2013; 443(1-2):9-16
-
(2013)
Int J Pharm
, vol.443
, Issue.1-2
, pp. 9-16
-
-
Yu, Y.1
Desjardins, C.2
Saxton, P.3
-
85
-
-
80955181061
-
Efficacy ans safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review
-
Oostendorp L, Stalmeier P, van der Graff W, Ottevanger P. Efficacy ans safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol 2011;12:1053-61
-
(2011)
Lancet Oncol
, vol.12
, pp. 1053-1061
-
-
Oostendorp, L.1
Stalmeier, P.2
Van Der Graff, W.3
Ottevanger, P.4
-
87
-
-
84901387919
-
Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastatis, and increases survival in the PyMT metastatic breast cancer model
-
Abstract P4-15-12. 13 December
-
Smith BD, Kaufman MD, Hood MM, et al. Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastatis, and increases survival in the PyMT metastatic breast cancer model. (Abstract P4-15-12) Presented at San Antonio Breast Cancer. 13 December 2013
-
(2013)
Presented at San Antonio Breast Cancer
-
-
Smith, B.D.1
Kaufman, M.D.2
Hood, M.M.3
-
88
-
-
84857918226
-
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: A California cancer consortium trial
-
Gitlitz BJ, Tsao-Wei DD, Groshen S, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: A California cancer consortium trial. J Thorac Oncol 2012;7(3):574-8
-
(2012)
J Thorac Oncol
, vol.7
, Issue.3
, pp. 574-578
-
-
Gitlitz, B.J.1
Tsao-Wei, D.D.2
Groshen, S.3
|